Tinib Antineoplastic drugs

Tinib antineoplastic drug is a new class of biological targeted treatment of cancer. Nowadays, on the common market of our country, there are Gefitinib, Imatinib, Imatinib Mesylate, Nilotinib, Sunitinib and Lapatinib.

Gefitinib is a specific anti-tumor targeted therapy with high specificity which has been developed by AstraZeneca UK. It is the first kind of targeted drug for the treatment of non-small cell lung cancer (NSCLC). It would work by selectively inhibiting the signal transduction pathway of epidermal growth factor receptor tyrosine kinase (EGFR-TK).

Imatinib is a new 2-anilino pyrimidine tyrosine kinase inhibitor. And it can effectively inhibit Bcr-abl tyrosine kinase activity at the cellular level, which is the product of Ph chromosome abnormalities of Chronic Myelogenous Leukemia (CML). So Imatinib can selectively inhibit the Ber-abl positive cell lines proliferation and induce cell apoptosis the cells of patients who have been tortured by c Chronic Myelogenous Leukemia (CML).

Sunitinib is multi-targeted tyrosine kinase inhibitors, including platelet-derived growth factor receptor, vascular endothelial growth factor receptor activation and various forms of mutant stem cell factor receptor. It can inhibit the expression dysregulation of tumor cell RTKs and can inhibit the anti-tumor angiogenesis as well. Metabolization of Sunitinib relies on cytochrome P450 enzyme. Sunitinib is suitable for gastrointestinal stromal tumor of imatinib-resistant or treatment-progressors, or for the treatment of renal cell carcinoma.

---